Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome
27 avr. 2018 08h00 HE
|
Zogenix, Inc.
ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo Data Presented During Emerging Therapies Plenary Session...
Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
25 avr. 2018 08h00 HE
|
Zogenix, Inc.
Efficacy and Safety Data in Patients on ZX008 Who Previously Failed Stiripentol Treatment Prior to Entry into First Phase 3 Trial (Study 1) Comparable to Results from Full Study 1 Population Patients...
Zogenix to Participate in LEERINK Partners CNS Day
11 avr. 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
06 mars 2018 16h01 HE
|
Zogenix, Inc.
ZX008 Granted Breakthrough Therapy Designation in Dravet syndrome by FDALast patient randomized into second Phase 3 clinical trial of ZX008 in patients with Dravet syndrome, Study 1504Initiated global...
Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6
27 févr. 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference
08 févr. 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
06 févr. 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Completes Enrollment in Second ZX008 Phase 3 Clinical Trial in Dravet Syndrome
31 janv. 2018 16h05 HE
|
Zogenix, Inc.
Study 1504 Top-Line Data on Track for 2Q 2018 EMERYVILLE, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of...
Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
04 déc. 2017 08h00 HE
|
Zogenix, Inc.
ZX008 Patients More Likely to Achieve Clinically Meaningful Reduction in Seizure Frequency Compared to Those on Placebo Parents/Caregivers and Investigators Rated Patients Treated with ZX008 as Very...
Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome
29 nov. 2017 08h05 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...